UroGen Pharma Ltd. — Director's Dealing 2019

Sep 6, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2019-09-04

Reporting Person: Schoenberg Mark (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-09-04	Ordinary Shares	M	1041	—	Acquired	6350	Direct
2019-09-04	Ordinary Shares	S	343	$33.92	Disposed	6007	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-09-04	Restricted Stock Units (RSUs)	$	M	1041	Disposed		Ordinary Shares (1041)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.

F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.

F3: On December 7, 2017, the reporting person was granted restricted stock units ("RSUs") representing 12,500 ordinary shares. 1/3rd of the RSUs vested on December 4, 2018, with the balance vesting in equal quarterly installments thereafter over a period of two years.